BOBULSKY SUSAN sold $198K of ADPT
BOBULSKY SUSAN (Chief Commercial Officer, MRD) sold 11,000 shares of Adaptive Biotechnologies Corp (ADPT) at $18.00 ($0.20M total) on 2026-06-04 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the specific sale size, price ($18.00/share), and that it was executed under a pre-arranged 10b5-1 plan.
Market read
This is a routine insider-sale filing; it may marginally affect sentiment but lacks fundamental new information.
What to watch
Traders may want to compare this sale to prior insider activity (frequency/size) and whether there are concurrent operational or clinical catalysts in the same period.
Background
The article is a primary-source SEC Form 4 insider transaction disclosure for Adaptive Biotechnologies.
Ticker impact
Adaptive Biotechnologies insider Form 4 shows CCO Susan Bobulsky sold 11,000 shares for ~$198k under a 10b5-1 plan.
Low likelihood of sustained price impact; any effect is likely short-lived unless accompanied by other news.
The disclosure is a Form 4 insider sale (not a buy) but explicitly states a pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.
Market effects
No clear sector read-through from a single, modest insider sale under 10b5-1.
None.
None.
Counterpoint
Even with 10b5-1, repeated insider selling can coincide with management de-risking ahead of other company-specific developments not mentioned here.
Key entities
- issuerAdaptive Biotechnologies Corp
Company whose shares were sold by an insider; ticker ADPT.
- insiderSusan Bobulsky
Chief Commercial Officer (MRD) who sold 11,000 shares.